

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066056 A1

(51) International Patent Classification⁷: **A61K 31/496**,
31/4985

Science Park South, Third Avenue, Harlow, Essex CM19
5AW (GB).

(21) International Application Number: PCT/GB03/00462

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline,
CN925.1, 980 Great West Road, Brentford, Middlesex
TW8 9GS (GB).

(22) International Filing Date: 4 February 2003 (04.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0202680.5 5 February 2002 (05.02.2002) GB
0222616.5 30 September 2002 (30.09.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **GLAXO
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 ONN (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FOLEY, Andrew**
[IE/IE]; Department of Pharmacology, Conway Institute,
University College Dublin, Belfield, Dublin 4 (IE). **GAL-
LAGHER, Helen** [IE/IE]; Department of Pharmacology,
Conway Institute, University College Dublin, Belfield,
Dublin 4 (IE). **HAGAN, James** [GB/GB]; GlaxoSmithK-
line, New Frontiers Science Park South, Third Avenue,
Harlow, Essex CM19 5AW (GB). **REGAN, Ciaran**
[IE/IE]; Department of Pharmacology, Conway Institute,
University College Dublin, Belfield, Dublin 4 (IE). **UP-
TON, Neil** [GB/GB]; GlaxoSmithKline, New Frontiers

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: METHOD OF PROMOTING NEURONAL GROWTH

(57) Abstract: The present invention relates to a novel method of promoting neuronal growth within the central nervous system of a mammal and to compounds and pharmaceutical compositions for use in such a method.



WO 03/066056 A1

METHOD OF PROMOTING NEURONAL GROWTH

5 This invention relates to a novel method of promoting neuronal growth within the central nervous system of a mammal and to compounds and pharmaceutical compositions for use in such a method.

10 The widely held belief that the permanent loss of neurons associated with Alzheimer's or Parkinson's disease and injury such as stroke offers no possibility of cellular regeneration has been challenged by the extensive evidence for neural stem cells resident within the adult brain (Gage, F. H. (2000) *Science* **287**, 1433-1438). Neurogenesis and the synaptic plasticity of these newborn cells can be influenced by stress, an enriched environment and physical exercise (van Praag *et al.*, (1999) *Proc. Natl. Acad. Sci. USA* **96**, 13427-13431; Nilsson *et al.*, (1999) *J. Neurobiol.* **39**, 569-578). New cells generated in situ may also be manipulated pharmacologically and integrated into the existing circuitry. Serotonin, via the 5HT1A receptor, or chronic treatment with antidepressants, such as tranlycypromine, reboxetine or fluoxetine, stimulate hippocampal neurogenesis (Gould, E. (1999) *Neuropsychopharm.* **21**, 46S-51S; Malberg *et al.*, (2000) *J. Neurosci.* **20**, 9104-9110; Brezun and Daszuta (2000) **12**, 391-396). By contrast, the competitive NMDA receptor antagonist CGP43487 and opiate receptor agonist morphine reduce the rate of hippocampal neurogenesis (Eisch *et al.*, (2000) *Proc. Natl. Acad. Sci. USA* **97**, 7579-7584; Nacher *et al.*, (2001) *Eur. J. Neurosci.* **13**, 512-520).

25 A convergent set of data suggests the polysialylated form of the neural cell adhesion molecule (PSA-NCAM) to be implicated in the support of structural reorganizations and synaptic plasticity in areas such as the hypothalamus, olfactory bulb, and hippocampus of the adult nervous system (Seki, T. and Arai, Y. (1993) *Neurosci. Res.* **17**, 265-290; Kiss, J. and Rougon, G. (1997) *Curr. Opin. Neurobiol.* **7**, 640-646). Structural plasticity in the adult hippocampus of several mammalian species, including humans, includes the proliferation of neural precursors in the dentate subgranular zone and these newly generated granule neurons transiently express NCAM PSA (Seki, T. and Arai, Y. (1993) *J. Neurosci.* **13**, 2351-2358). Newly generated, polysialylated neurons, presumably arising from the anterior subventricular zone, are also found in associational areas of the cortex, such as the temporal lobe (Doetsch *et al.* (1997) *J. Neurosci.* **17**, 5046-5061; O'Connell *et al.*, (1997) *J. Neurochem.* **68**, 2538-2546; NiDhuill *et al.* (1999) *J. Neurosci. Res.* **55**, 99-106; Gould *et al.* (1999) *Science* **286**, 548-525). Moreover, during the consolidation of either avoidance conditioning or spatial learning paradigms, transient increases in polysialylated cell frequency occur in the 12h post-training period and are necessary for the accompanying dendritic remodeling observed in rat hippocampus and medial temporal lobe (Fox *et al.* (1995) *J. Neurochem.* **65**, 2796-2799; Murphy *et al.* (1996) *J. Neurochem.* **67**, 1268-1274; O'Connell *et al.* (1997) *J. Neurochem.* **68**, 2538-2546; O'Malley *et al.* (1998) *Neuroscience* **87**, 607-613; O'Malley *et al.* (2000) *Neuroscience* **99**, 229-232; Fox *et al.* (2000) *J. Neurobiol.* **45**, 135-141).

Multiple 5-hydroxytryptamine (5-HT) receptors have been identified (5-HT_{1A}/1B/1D/1E/1F, 5-HT_{2A}/2B/2C, 5-HT_{3A}/3B, 5-HT_{4A}/4B, 5-HT_{5A}/5B, 5-HT₆ and 5-HT_{7A}/7B/7C/7D) and extensive evidence suggests that 5-HT receptors have a role in learning and memory. A number of antagonists of the 5-HT₆ sub group of 5-HT receptors have been discovered and published in International publication numbers WO 98/27081, WO 98/27058, WO 99/02502, WO 99/37623, WO 99/42465, WO 00/12073, WO 00/12623, WO 01/32646 (all in the name of SmithKline Beecham plc) and these compounds are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease (cognitive memory enhancement), sleep disorders (including disturbances of Circadian Rhythm), feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, ADHD, disorders associated with spinal trauma and/or head injury such as hydrocephalus and certain GI disorders such as IBS. Relatively high levels of the 5HT₆ receptors are found in the molecular layer of the hippocampal dentate gyrus (Gérald *et al.* (1997) *Brain Res.* **746**, 207-219) where their antagonism may enhance excitability directly or through an intervening inhibitory action on the GABAergic interneurons.

One such compound disclosed as Example 83 in WO 98/27081 is 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl)amide hydrochloride, which has also been referred to in the literature as SB-271046. SB-271046 has been characterised as a potent antagonist of human (pK_i 8.8-8.9) and rat (pK_i 9.0) 5-HT₆ receptors. In addition, the compound is over 200-fold selective for 5-HT₆ receptors versus 55 other receptors, binding sites and ion channels. SB-271046 is orally bioavailable and increases seizure threshold (an action indicative of anticonvulsant properties) in the rat maximal electroshock seizure threshold test over a wide-dose range (0.1-30mg/kg) (Routledge *et al.* (2000) *British J. Pharm.* **130**, 1606-1612). At 10mg/kg p.o., SB-271046 also produces significant improvements in retention of a spacial memory task in the rat thus highlighting its potential for enhancing cognitive processes in humans (Rogers, D. C. & Hagan, J. J. (2001) *Psychopharmacology* **158**: 114-119).

The inventors of the present invention have found that 5-HT₆ receptor antagonists are capable of increasing basal and learning-induced polysialylated neuron cell frequency in brain regions such as the rat medial temporal lobe and associated hippocampus.

Thus, according to the present invention we provide a method of promoting neuronal growth within the central nervous system of a mammal which comprises the step of administering a 5-HT₆ receptor antagonist.

Preferably, neuronal growth will be promoted within the regions primarily responsible for learning and memory functions, such as the hippocampus or medial temporal lobe regions of the central nervous system of a mammal.

Preferably, the 5-HT₆ receptor antagonist will be administered in the form of a pharmaceutical composition.

5 Diseases which can be treated by the method of the present invention include neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease and stroke.

Wherein said 5-HT₆ receptor antagonist is administered in the form of a pharmaceutical composition it may be prepared in admixture with one or more pharmaceutically acceptable excipients.

10 As a second aspect of the present invention we provide a use of a 5-HT₆ receptor antagonist in the manufacture of a medicament for promoting neuronal growth within the central nervous system of a mammal.

15 As a further aspect of the present invention we provide a pharmaceutical composition comprising a 5-HT₆ receptor antagonist for use in promoting neuronal growth within the central nervous system of a mammal.

20 A pharmaceutical composition of the invention, which may be prepared suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

25 Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

30 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional
35 flavourings or colourants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or a pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or
40 dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after

5 filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

10 The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 200 mg, for example 20 to 40 mg; and such unit doses will preferably be administered once a day, although administration more than once a day may be required; and such therapy may extend for a number of weeks or months.

20 5-HT₆ receptor antagonists known in the art are of potential use in promoting neuronal growth within the central nervous system of a mammal. For example, those 5-HT₆ receptor antagonists disclosed in International publication numbers WO 98/27081, WO 98/27058, WO 99/02502, WO 99/37623, WO 99/42465, WO 00/12073, WO 00/12623, WO 01/32646 (all in the name of SmithKline Beecham plc) herein incorporated by reference.

25 In one preferred aspect of the present invention, said 5-HT₆ receptor antagonist is 5-chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl)amide or a pharmaceutically acceptable salt or solvate thereof, most preferably as the hydrochloride salt.

30 In a second preferred aspect of the present invention, said 5-HT₆ receptor antagonist is N-(3,5-dichloro-2-methoxy-phenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide or a pharmaceutically acceptable salt or solvate thereof, most preferably as the hydrochloride salt.

35 The present invention is illustrated by reference to the following Examples:

Examples

(a) General Experimental

40 Experimentally naïve postnatal day 80 (at the time of NCAM-PSA assessment) male Wistar rats were employed in all studies. All animals were housed singly and maintained at 22±2°C on a standard 12h-light/dark cycle with food and water available ad libitum. Animals were introduced to the experimental holding rooms at least 3 days prior to the commencement of any study.

Within the Examples, references to SB271046 should be interpreted as references to 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl)amide hydrochloride and references to SB399885 should be interpreted as references to N-(3,5-dichloro-2-methoxy-phenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide hydrochloride.

(b) Quantitative analysis of NCAM PSA expression

(i) Cryosection technique

Freshly dissected whole rat brain was carefully coated in optimum cutting temperature (OCT) compound and lowered into a Cryoprep freezing apparatus containing dry-ice-cooled n-hexane. The function of the OCT compound and n-hexane was to provide an even freezing of the tissue, thus avoiding freezing artefacts. Horizontal sections for all studies were cut semi-automatically or automatically on a Microm Series 500 cryostat. Fresh, frozen brain sections (12µm) were cut at -15°C, while cryoprotected. All sections were prepared on the day of the experiment and were not pre-cut and stored frozen. For the analysis of the NCAM PSA-positive hippocampal dentate granule cell layer/hilus border cells, 10 alternate sections were taken at a level equivalent to -5.6mm below Bregma (Paxinos and Watson, 1986), at which level this cell population was found to be maximal.

The frequency of polysialylated neurons in the rat medial temporal lobe was also examined following chronic exposure to 5-HT₆ antagonist. These polysialylated neurons, located in layer II of the entorhinal and perirhinal cortex and exhibiting a dorso-ventral increase in frequency, were examined at bregma levels -7.1, -7.6, -8.1 and -8.6.

(ii) Immunohistochemical protocol

Horizontal cryosections were cut from the frozen tissue at various levels with reference to Bregma (see above), these were thaw-mounted onto glass slides, which were coated with poly-l-lysine diluted 1:1 in dH₂O, and immersion fixed for 30 minutes with 70% ethanol. The sections were then washed twice for 10 minutes each in 0.1M phosphate buffered saline (PBS) and incubated for 20 hours in a humidified chamber at room temperature with the primary antibody diluted 1:500 in PBS containing 1% bovin serum albumin (w/v) and 1% normal goat serum (v/v) to reduce non-specific staining. The humidified chamber prevented the sections from evaporating. The primary antibody was a monoclonal raised against PSA, which was provided by Professor G. Rougon (CNRS UMR 6545, 13288 Marseille, France). On completion of the primary antibody incubation, the sections were washed twice for ten minutes each in PBS and incubated at room temperature for 3 hours in the humidified chamber with the secondary antibody, at a dilution factor of 1:100, again in PBS containing 1% BSA and 1% NGS. The secondary antibody was a goat anti-mouse IgM conjugated to fluorescein (FITC). Following the second incubation, the sections were again washed twice for ten minutes each in PBS, mounted in the fluorescence enhancing medium Citifluor[®] and observed for fluorescence with a Leitz DM RB fluorescent microscope.

(iii) Quantitative evaluation of NCAM PSA expression

Quantitative image analysis was performed using the Leica Quantimet 500[®], a P.C.-based software package, which was connected to the fluorescence microscope with a high sensitivity CCD video camera. Each microscope lens was calibrated for length and area measurements using a 1mm graticule. The total number of NCAM PSA-immunoreactive neurons on the right dentate granule cell layer/hilar border were counted in 7 alternate 12µm sections commencing -5.6mm from Bregma (Paxinos and Watson, 1986), to preclude double counting of the 5-10µm perikarya. Cell identification was aided by the use of the nuclear counter-stain propidium iodide (40ng/ml PBS; 60 sec). The number of cells was then divided by the total area of the dentate granule cell layer and multiplied by the average granule cell layer area for a p80 rat, which is $0.15 \pm 0.01\text{mm}^2$ at this level. This was done for each section and a mean±SEM was calculated for each brain with the results expressed as PSA-positive cells per unit area. These results were then used to generate the mean±SEM for each animal group. Cell identification was again aided by the use of the nuclear counter-stain propidium iodide (40ng/ml PBS; 60 sec) with the use of alternate sections eliminating the possibility of double counting. Cell counts were divided by the length of the cortex and multiplied by the average length of the cortex, which was taken to be 10mm. This was completed for each section and a mean±SEM was calculated for each brain with the results expressed as PSA-positive cells per unit length. These results were used to generate the final mean±SEM for each animal group.

(iv) Water maze training

25 1. Behavioural assessment

In this protocol animals were introduced to the training environment 5 days prior to training, and individually housed according to standard conditions. Animals were left to habituate to the environment for days 1 and 2 with no handling, on days 3, 4 and 5 animals were handled, their weight monitored and spontaneous behaviour was assessed in open field apparatus for 5 minutes. Open field studies formed an essential part of all training procedures. The open field apparatus consisted of black-painted wood 620mm long, 620mm wide, and 150mm high. The white-painted floor of the apparatus was ruled from side to side, dividing it into a series of boxes 77 x 77mm square. Locomotor activity was measured as the number of lines crossed over 300 seconds. Other behaviours assessed were rearing, grooming, piloerection, defecation and posture. These behavioural assessments were invaluable for detecting animals failing to respond to the training schedule or possible unwarranted drug effects that may confound test results.

40 2. Apparatus

The water maze apparatus consisted of a circular pool (1m diameter, 80cm high) specially constructed from established designs in black Perspex. The temperature was maintained at 26°C by way of a heating element, which was covered by a false bottom with a pump to

circulate the water. A platform (11cm diameter) was submerged 1.5cm below the water surface, also constructed from black Perspex. During training the platform was hidden in one quadrant of the maze 30cm from the sidewall. The black Perspex of the maze and platform offer no intramaze cues to guide escape behaviour. However, the training room offers several strong extramaze visual cues to aid the formation of the spatial map necessary for escape learning. An automated tracking system "Water maze 3.1" was employed. This program analyses video images acquired via digital camera and image acquisition board, determining path-length, duration, maximum speed, angle (angle between the initial direction of swim and the endpoint (platform)), and the number of entries and duration of swim spent in each quadrant of the water maze.

3. Single session water maze training

This was the standard paradigm employed to study molecular events associated with learning and memory consolidation, as described previously publications (Murphy *et al.* (1996) *J. Neurochem.* **67**, 1268-1274). Each trial starts with the rat placed facing the wall of the maze at one of three designated locations. The rat was allowed to explore the maze and the time taken to find the hidden platform within a 60s criterion period was defined as the escape latency time. On the first trial, rats failing to locate the platform within the 60s period were placed on it for 10 seconds. In subsequent trials animals failing to locate the platform were not shown it again. Escape latencies were measured over 5 trials with an inter-trial rest interval of 300 seconds.

Animals from acute and chronic treatment groups were trained as outlined above. All animals acquired the task as indicated by the decrease in latency to find the platform between trial 1 and trial 5. [Acute study: drug-treated and trained – $F(4,19)=3.531$; $p=0.032$; untreated and trained – $F(4,19)=7.748$; $p=0.0014$] [Chronic study: drug-treated and trained – $F(4,19)=13.345$; $p<0.0001$; untreated and trained – $F(4,19)=1.455$; $p=0.2647$] Subsequently, 12 hours following cessation of trial 5 the animals were sacrificed by cervical dislocation, brain tissue dissected free and cryopreserved for quantification of NCAM polysialylation as above.

(v) Data analysis

NCAM PSA-positive cell numbers were obtained from each animal group. Results were expressed as mean \pm SEM with at least 3-6 values per group and analysed by ANOVA or unpaired non-parametric, Student's t-test, as indicated.

(c) Quantitative analysis of bromodeoxyuridine (BrdU) expression

(i) Tissue preparation

Following transcardial perfusion with a 4% paraformaldehyde solution at pH 7.4, brains are removed and stored in the same fixative overnight. Subsequently, the brains are carefully coated in optimum cutting temperature (OCT) compound and lowered into a Cryoprep

freezing apparatus containing dry-ice-cooled n-hexane. The function of the OCT compound and n-hexane is to provide an even freezing of the tissue, thus avoiding freezing artifacts.

(ii) Cryosection technique

5 Sections for all studies are cut manually on a Microm Series 500 cryostat and are horizontal in orientation. Fresh, frozen brain sections (50µm) are cut at -25°C, while cryoprotected. All sections are prepared on the day of the experiment and are not pre-cut and stored frozen. This provides for optimal tissue morphology. For the analysis of the BrdU-immunopositive
10 hippocampal dentate granule cell layer cells, 8 free-floating sections are obtained from each brain and stored in cryoprotectant (0.32M Sucrose). These are taken at 500µm intervals commencing at a level equivalent to -4.1mm below Bregma.

(iii) Immunohistochemical protocol

15 The sections are transferred from cryoprotectant and washed three times for 5 minutes each in a 0.1M PBS solution containing 5mM MgCl₂ and 1mM CaCl₂ (required for the stability of DNase enzyme). For DNA denaturation the sections are incubated at 37°C for 1 hour in DNase (1000 units/ml). The sections are again washed and blocked with 10%w/v NGS for 30 minutes, then incubated for 20 hours at room temperature with the primary antibody (anti-BrdU rat IgG, Harlan UK), diluted 1:100 in PBS containing 10% NGS (v/v) to reduce
20 non-specific staining. Subsequently, the sections are washed and incubated at room temperature for 1 hour with the secondary antibody (Alexa 488-conjugated goat anti-rat IgG, Molecular Probes UK), diluted 1:200, again in PBS containing 10% NGS. Following the second incubation, the sections are again washed and mounted in Citifluor.

25 (iv) Quantitative evaluation of BrdU expression

The frequency of BrdU-immunoreactive cells in the right dentate granule cell layer is counted in 10 random sections throughout the hippocampus. Then quantitative image analysis is performed using Leica Quantimet 500 software, to determine the area of the granule cell layer in each section and then the granule cell layer volume by the Cavalieri
30 method. The total number of BrdU-immunopositive cells per granule cell layer is then established from the resultant cell density and granule cell layer volume, and is used to generate the mean±SEM number of BrdU-immunopositive cells per granule cell layer for each animal group. Statistical analysis employs the Student's *t*-test.

35 Example 1: Effect of chronic administration of SB271046 upon neuronal cell growth within the hippocampus

Postnatal day 40 male animals (maintained in accordance with the general procedure detailed in section (a) above) were administered 3, 10 or 20 mg/kg SB271046 for 40 days by gavage. Drug administration ceased 24h prior to animal sacrifice. Animal weight gain and
40 general physical condition was monitored daily. Methylcellulose (1% w/v) treated controls and use of the antipsychotic clozapine were employed for comparison. NCAM PSA expression was then quantified for each of the 5 groups of animals (eg. control, 3, 10 and 20

mg/kg SB271046 and clozapine) in accordance with the general procedure detailed in sections (b)(i)-(iii) above.

The resultant data obtained was analysed as described in section (b)(v) above and SB271046 was found to significantly increase the frequency of polysialylated neurons in the subventricular zone of the rat hippocampal dentate gyrus, in a dose-dependent manner, as detailed in Table 1 below. This effect was not observed in the vehicle-treated control or with the antipsychotic clozapine. These polysialylated neurons are represented by fluorescent cells located at the granule cell layer/hilar border and their dendrites extend into the molecular layer of the hippocampal dentate gyrus.

TABLE 1

15	Treatment	PSA immunopositive cell frequency
	control	63.4±3.5
	SB271046 (3mg/kg)	70.3±3.9
	SB271046 (10mg/kg)	82.4±1.7*
20	SB271046 (20mg/kg)	85.8±8.4*
	clozapine (5mg/kg)	69.8±1.6

* P<0.05 versus control, one-way ANOVA; n=6 in all cases.

The frequency of polysialylated neurons in the rat medial temporal lobe was also increased following chronic exposure to SB271046 (20mg/kg), as detailed in Table 2 below. These polysialylated neurons are located in layer II of the entorhinal and perirhinal cortex and exhibit a dorso-ventral increase in frequency. At bregma levels -7.1, -7.6 and -8.6 polysialylated cell frequency was significantly increased as compared to the methylcellulose-treated control animals. No significant increase in polysialylated cell frequency was observed at bregma level -8.1.

TABLE 2

35	Bregma level (mm)	PSA immunopositive cell frequency	
		Control	SB271046 (20mg/kg) -treated
	-7.1	47.3±4.2	61.7±1.7*
40	-7.6	52.6±3.8	69.9±0.9*
	-8.1	111.1±6.9	125.4±3.5
	-8.6	141.3±4.9	178.3±12.2*

Control group is significantly different to treated group by two-way ANOVA. Significant differences between each bregma level is indicated by an asterisk ($p < 0.05$, unpaired, non-parametric Student's t-test), $n=3$ in all cases.

Example 2: Effect of acute and chronic administration of SB271046 upon learning induced activation of neuronal cell growth within the hippocampus

Postnatal day 80 male animals (maintained in accordance with the general procedure detailed in section (a) above) were administered 20 mg/kg SB271046 by gavage 30min before water maze training in accordance with the protocol described in section (b)(iv) above (acute administration) or postnatal day 40 male animals were administered 20 mg/kg SB271046 for 40 days by gavage and water maze trained in accordance with the protocol described in section (b)(iv) above on postnatal day 80 (chronic administration). Methylcellulose (1% w/v) treated controls were employed for comparison. NCAM PSA expression was then quantified for each of the 4 groups of animals (eg. untrained and trained controls and animals administered with 20mg/kg SB271046) in accordance with the general procedure detailed in sections (b)(i)-(iii) above.

The resultant data obtained was analysed as described in section (b)(v) above and acute administration of SB271046 was found to significantly increase the frequency of polysialylated neurons in the subventricular zone of the rat hippocampal dentate gyrus at 12h following water maze training as compared to untrained animals receiving the drug and, also, in respect of the trained but drug-naïve animals (Table 3). Similar results were obtained with animals chronically exposed to SB271046 (Table 4).

TABLE 3

Treatment	PSA immunopositive cell frequency
1. Untrained control	65.2 \pm 2.4
2. 12h post-training control	85.3 \pm 1.8
3. SB271046 (20mg/kg)-treated untrained control	64.2 \pm 4.3
4. SB271046 (20mg/kg)-treated 12h post-training	96.0 \pm 5.5

 Statistical evaluation of Table 3

	Data points compared	p value
5	1 versus 2	0.0003
	3 versus 4	0.0044
	2 versus 4	0.0361

10 Unpaired non-parametric, Student's t-test, n=3-6 in all cases.

TABLE 4

	Treatment	PSA immunopositive cell frequency
15	1. Untrained control	63.4±3.5
	2. 12h post-training control	81.1±1.6
20	3. SB271046 (20mg/kg)-treated untrained control	85.8±1.3
25	4. SB271046 (20mg/kg)-treated 12h post-training	109.8±1.8

 Statistical evaluation of Table 4

	Data points compared	p value
30	1 versus 2	0.009
	3 versus 4	0.0484
	2 versus 4	0.0002

35 Unpaired non-parametric, Student's t-test, n=3 in all cases.

Example 3: Effect of chronic administration of SB399885 upon neuronal cell growth within the hippocampus

40 Postnatal day 40 male animals (maintained in accordance with the general procedure detailed in section (a) above) were administered 3, 10 or 20 mg/kg SB399885 for 40 days by gavage. Drug administration ceased 24h prior to animal sacrifice. Animal weight gain and general physical condition was monitored daily. Methylcellulose (1% w/v) treated controls were employed for comparison. An additional SB271046 (20mg/kg) treatment group was

utilised to ensure comparable results with previous studies. NCAM PSA expression was then quantified in accordance with the general procedure detailed in sections (b)(i)-(iii) above.

5 The resultant data obtained was analysed as described in section (b)(v) above and SB399885 was found to significantly increase the frequency of polysialylated neurons in the subventricular zone of the rat hippocampal dentate gyrus, in a dose-dependent manner, as detailed in Table 5 below. This effect was not observed in the vehicle-treated control. These polysialylated neurons are represented by fluorescent cells located at the granule cell
10 layer/hilar border and their dendrites extend into the molecular layer of the hippocampal dentate gyrus.

TABLE 5

15	Treatment	PSA immunopositive cell frequency
	control	58.7±3.9
	SB399885 (3mg/kg)	81.4±5.3*
20	SB399885 (10mg/kg)	87.4±5.4*
	SB399885 (20mg/kg)	104.2±4.4*
	SB271046 repeat (20mg/kg)	78.3±3.4*

* P<0.05 versus control, Student's t-test; n=6 in all cases.

25 SB399885 versus control, one-way ANOVA, F(3,23)=15.3; P<0.0001

Moreover, analysis of variance shows the dose dependent increase in basal frequency of hippocampal polysialylated neurons following chronic SB399885 treatment was significantly greater than that observed following chronic SB271046 administration in
30 Example 1 above (F[1,21]=5.882; P=0.0244). Furthermore, in this experiment, there was no difference in the frequency of polysialylated neurons in the subventricular zone of the rat hippocampal dentate gyrus in SB271046-treated animals as compared to that observed in Example 1.

35 Example 4: Effect of chronic administration of SB399885 on hippocampal polysialylated neuron cell frequency following water maze training.

Postnatal day 40 male animals (maintained in accordance with the general procedure detailed in section (a) above) were administered 20 mg/kg SB399885 for 40 days by gavage and water maze trained in accordance with the protocol described in section (b)(iv) above
40 on postnatal day 80 (chronic administration). Methylcellulose (1% w/v) treated controls were employed for comparison. NCAM PSA expression was then quantified in accordance with the general procedure detailed in sections (b)(i)-(iii) above.

The resultant data obtained was analysed as described in section (b)(v) above and chronic administration of SB399885 was found to significantly increase the frequency of polysialylated neurons in the subventricular zone of the rat hippocampal dentate gyrus at 12h following water maze training as compared to untrained animals receiving the drug and, also, in respect of the trained but drug-naïve animals (Table 6).

TABLE 6

10	Treatment	PSA immunopositive cell frequency
	1. Untrained control	58.7±3.9
15	2. 12h post-training control	91.3±6.5
	3. SB399885 (20mg/kg)-treated untrained control	104.2±4.4
20	4. SB399885 (20mg/kg)-treated 12h post-training	125.9±4.7
25	Statistical evaluation	
	Data points compared	p value
	1 versus 2	0.0027
	3 versus 4	0.0189
	2 versus 4	0.0127
30	Unpaired non-parametric, Student's t-test, n=3 in all cases.	

Moreover, the significant increase in the observed frequency of hippocampal polysialylation neurons 12h following water maze training in those animals chronically administered SB399885 (20mg/kg), was significantly greater than that observed following SB271046 treatment in Example 2 (Student's t-test; P=0.0337).

Example 5: Effect of chronic administration of SB271046 or SB399885 on hippocampal neurogenesis.

Postnatal day 40 male animals (maintained in accordance with the general procedure detailed in section (a) above) were administered 20 mg/kg SB271046 or SB399885 for 40 days by gavage (chronic administration). For the last eight days of the study animals from each treatment group are administered bromodeoxyuridine (BrdU, 100mg/kg, i.p.), which is a marker of DNA synthesis that has been used extensively to study brain neurogenesis

(Gage (2002) J. Neurosci. **22**, 612-613). Drug administration ceased 24h prior to animal sacrifice. Animal weight gain and general physical condition was monitored daily. Methylcellulose (1% w/v) treated controls were employed for comparison. BrdU expression was then quantified in accordance with the general procedure detailed in section (c) above.

Neither SB271046 nor SB399885 chronic administration significantly altered the expression of BrdU-immunopositive cells in the hippocampal dentate granule cell layer as compared to vehicle-treated controls, as detailed in Table 7 below, demonstrating the ability of both compounds to activate NCAM PSA expression without altering neurogenic rate.

TABLE 7

Treatment	BrdU-immunopositive cell number/granule cell layer
control	2432±435.8
SB271046 (20mg/kg)	2332±136.5
control	2456.7±250.9
SB399885 (20mg/kg)	2296.7±49.1

The patents and patent applications described in this application are herein incorporated by reference.

CLAIMS

1. A method of promoting neuronal growth within the central nervous system of a mammal which comprises the step of administering a 5-HT₆ receptor antagonist.
- 5 2. A method according to claim 1 wherein said 5-HT₆ receptor antagonist is administered in the form of a pharmaceutical composition.
- 10 3. A method according to claim 1 or claim 2 wherein said 5-HT₆ receptor antagonist is 5-chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl)amide or a pharmaceutically acceptable salt or solvate thereof.
- 15 4. A method according to claim 3 wherein the pharmaceutically acceptable salt is the hydrochloride.
5. A method according to claim 1 or claim 2 wherein said 5-HT₆ receptor antagonist is N-(3,5-dichloro-2-methoxy-phenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide or a pharmaceutically acceptable salt or solvate thereof.
- 20 6. A method according to claim 5 wherein the pharmaceutically acceptable salt is the hydrochloride.
- 25 7. Use of a 5-HT₆ receptor antagonist in the manufacture of a medicament for promoting neuronal growth within the central nervous system of a mammal.
8. Use according to claim 7 wherein said 5-HT₆ receptor antagonist is administered in the form of a pharmaceutical composition.
- 30 9. Use according to claim 7 or claim 8 wherein said 5-HT₆ receptor antagonist is 5-chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl)amide or a pharmaceutically acceptable salt or solvate thereof.
- 35 10. Use according to claim 9 wherein the pharmaceutically acceptable salt is the hydrochloride.
11. Use according to claim 7 or claim 8 wherein said 5-HT₆ receptor antagonist is N-(3,5-dichloro-2-methoxy-phenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide or a pharmaceutically acceptable salt or solvate thereof.
- 40 12. Use according to claim 11 wherein the pharmaceutically acceptable salt is the hydrochloride.

13. A pharmaceutical composition comprising a 5-HT₆ receptor antagonist for use in promoting neuronal growth within the central nervous system of a mammal.

5 14. A pharmaceutical composition according to claim 13 wherein said 5-HT₆ receptor antagonist is 5-chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl)amide or a pharmaceutically acceptable salt or solvate thereof.

10 15. A pharmaceutical composition according to claim 14 wherein the pharmaceutically acceptable salt is the hydrochloride.

16. A pharmaceutical composition according to claim 13 wherein said 5-HT₆ receptor antagonist is N-(3,5-dichloro-2-methoxy-phenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide or a pharmaceutically acceptable salt or solvate thereof.

15 17. A pharmaceutical composition according to claim 16 wherein the pharmaceutically acceptable salt is the hydrochloride.

20

INTERNATIONAL SEARCH REPORT

PCT/GB 03/00462

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/496 A61K31/4985

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, EMBASE, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 6 423 717 B1 (WYMAN PAUL ADRIAN ET AL) 23 July 2002 (2002-07-23) cited in the application column 7, line 8-14; claims 1,8,11; examples 72,83	1-17
X	----- MIGUEL-HIDALGO, J.-J.: "SB-271046 SmithKline Beecham" CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 2, no. 1, 2001, pages 118-122, XP008016781 page 118, left-hand column, paragraphs 1-4 -----	1-17

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family.

Date of the actual completion of the international search

20 May 2003

Date of mailing of the international search report

28/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beyss, E

INTERNATIONAL SEARCH REPORT

PCT/GB 03/00462

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1, 2, 7, 8, 13 all in part, 3, 4, 9, 10, 14, 15

Pharmaceutical composition containing
5-chloro-3-methylbenzo[b]thiophene-2-sulfonic acid
(4-methoxy-3-piperazin-1-ylphenyl)amide and its use

2. Claims: 1, 2, 7, 8, 13 all in part, 5, 6, 11, 12, 16, 17

Pharmaceutical composition containing
N-3,5-dichloro-2-methoxy-phenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide and its use

INTERNATIONAL SEARCH REPORT

PCT/GB 03/00462

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6423717	B1	23-07-2002	AU 729056 B2	25-01-2001
			AU 6090498 A	15-07-1998
			BG 103530 A	31-01-2000
			BR 9713734 A	28-03-2000
			CN 1246116 A	01-03-2000
			CZ 9902203 A3	17-11-1999
			EA 2351 B1	25-04-2002
			WO 9827081 A1	25-06-1998
			EP 0946539 A1	06-10-1999
			HU 0000658 A2	28-02-2001
			JP 2001506646 T	22-05-2001
			NO 993003 A	18-06-1999
			NZ 335970 A	26-10-2001
			PL 334337 A1	28-02-2000
			SK 80899 A3	14-02-2000
			TR 9901361 T2	23-08-1999
			TW 418205 B	11-01-2001
			ZA 9711319 A	17-06-1999
